Detheux Michel 4

What Happened

• Michel Detheux, a director of Vor Biopharma (VOR), was granted a derivative equity award of 57,162 shares on June 11, 2026. The reported acquisition price is $0.00, so no cash was paid for the award at grant.

Key Details

• Transaction date: 2026-06-11; Form 4 filed: 2026-06-12 (timely).
• Transaction type/code: A (grant/award/other acquisition); 57,162 shares acquired at $0.00.
• Vesting: One thirty-sixth of the shares vests and becomes exercisable on July 11, 2026 and each month thereafter, subject to continued service (i.e., monthly vesting over 36 months).
• Shares owned after the transaction: not specified in the provided details.
• No 10b5-1 plan, tax-withholding, or cashless exercise reported in the filing.

Context

• This is a time‑based equity award (derivative) that vests monthly over three years—common for aligning directors/executives with long‑term shareholder interests. Because the grant was at $0.00 and not an open‑market purchase or sale, it does not represent an immediate cash transaction or a realized gain/loss.
• Such grants are routine compensation-related awards and should be viewed as part of standard equity‑based pay rather than a direct signal to buy or sell shares.